-
Association between pre-radiation therapy PSA levels and radiation therapy failure after prostatectomy: a propensity score matched analysis Prostate Int. (IF 3.0) Pub Date : 2024-03-11 Younsoo Chung M.D., Sang Hun Song M.D. Ph.D., Hakmin Lee M.D. Ph.D., Jong Ho Park M.D., Sung Kyu Hong M.D. Ph.D.
We sought to determine the association between the pre-radiation therapy prostate-specific antigen (pre-RT PSA) 0.5 and RT failure in post-radical prostatectomy (post-RP) patients. Our study also investigated the prognostic factors for the failure of RT given concurrently with HT after RP. We retrospectively reviewed our institutional RP data from July 2004 and November 2021. Patients without concurrent
-
The relationship between depression, anxiety and lower urinary tract symptoms in men Prostate Int. (IF 3.0) Pub Date : 2024-02-27 Yu Seob Shin, Kiran Kumar Soni, Dong Yun Lee, Sung Chul Kam
Patients with lower urinary tract symptoms (LUTS) often experience comorbid depression and anxiety, yet the mechanisms underlying this association remain incompletely understood. This prospective study aimed to investigate the relationship between depression, anxiety, and LUTS in men. A prospective study was conducted with 350 male patients who underwent urologic examinations at our institution from
-
Exploring the Potential of Ex-vivo 7-T MRI on Patients with Clinically Significant Prostate Cancer: Visibility and Size Perspective Prostate Int. (IF 3.0) Pub Date : 2024-02-22 Hyungwoo Ahn, Jung Kwon Kim, Sung Il Hwang, Sung Kyu Hong, Seok-Soo Byun, Sang Hun Song, Gheeyoung Choe, Hye Mi Jee, Sung Woo Park
Despite progress in multiparametric MRI, issues of prostate cancer invisibility and underestimated tumor burden persist. This study investigates the potential of ultra-high field MRI at 7-T in an ex-vivo setting to address these limitations. This prospective study included 54 tumors from 20 treatment-naïve clinically significant prostate cancer patients, confirmed by biopsy, despite negative findings
-
Association between pelvic lymph node dissection and survival among patients with prostate cancer treated with radical prostatectomy Prostate Int. (IF 3.0) Pub Date : 2024-02-07 Isaac E. Kim, Aaron H. Wang, George S. Corpuz, Preston C. Sprenkle, Michael S. Leapman, Joseph M. Brito, Joseph Renzulli, Isaac Yi Kim
Although the clinical benefits of pelvic lymph node dissection (PLND) at the time of radical prostatectomy for prostate cancer remain uncertain, major guidelines recommend PLND based on risk profile. Thus, the objective of this study was to examine the association between PLND and survival among patients undergoing RP stratified by Gleason grade group (GG) with the aim of allowing patients and physicians
-
Corrigendum to Screening and validation of novel serum panel of microRNA in stratification of prostate cancer.Prostate International;11(2023);150-158 Prostate Int. (IF 3.0) Pub Date : 2024-01-20 Anveshika Manoj, Mohammad Kaleem Ahmad, Gautam Prasad, Durgesh Kumar, Abbas Ali Mahdi, Manoj Kumar
Abstract not available
-
A novel anterior approach that involves Retzius space development between the umbilical ligaments is associated with a lower incidence of postoperative inguinal hernia in robotic radical prostatectomy Prostate Int. (IF 3.0) Pub Date : 2024-01-06 Satoshi Washino, Shozaburou Mayumi, Kimitoshi Saito, Kai Yazaki, Yuhki Nakamura, Tomoaki Miyagawa
Background To facilitate robotic radical prostatectomy (RP), we developed a novel anterior approach that utilizes a peritoneal incision between the umbilical ligaments to develop the Retzius space without contacting the internal inguinal rings, followed by closure of this space prior to prostatectomy and vesicourethral anastomosis. This approach could decrease the incidence of postoperative inguinal
-
Real-world effects of novel androgen receptor axis-targeted agents on oncological outcomes in non-metastatic castration-resistant prostate cancer: A multi-institutional retrospective study Prostate Int. (IF 3.0) Pub Date : 2023-12-19 Naoki Fujita, Shingo Hatakeyama, Ryuji Tabata, Kazutaka Okita, Koichi Kido, Itsuto Hamano, Toshikazu Tanaka, Daisuke Noro, Noriko Tokui, Yuichiro Suzuki, Takahiro Yoneyama, Yasuhiro Hashimoto, Satoshi Sato, Chikara Ohyama
Background The benefits of novel androgen receptor axis-targeted agents (ARATs) on oncological outcomes in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) in real-world settings are unclear. Methods This multi-institutional retrospective study included 178 patients with nmCRPC treated between September 2003 and August 2022. Patients were divided into two groups: those who
-
High-power holmium laser versus thulium fibre laser for endoscopic enucleation of the prostate in patients with glands larger than 80 ml: Results from the PEEL study group Prostate Int. (IF 3.0) Pub Date : 2023-12-13 Ee Jean Lim, Daniele Castellani, Bhaskar Kumar Somani, Mehmet Ilker Gökce, Khi Yung Fong, Fernando Gomez Sancha, Thomas R.W. Herrmann, Sarvajit Biligere, Azimdjon N. Tursunkulov, Marco Dellabella, Mario Sofer, Dmitry Enikeev, Vladislav Petov, Nariman Gadzhiev, Dean Elterman, Abhay Mahajan, Moises Rodriguez Socarras, Dilmurod S. Yunusov, Furkat Nasirov, Jeremy Yuen-Chun Teoh, Vineet Gauhar
Background Endoscopic enucleation of the prostate (EEP) has gained acceptance as an equitable alternative to transurethral resection of the prostate for benign prostate hyperplasia (BPH). Our primary aim is to compare peri-operative outcomes of EEP using thulium fibre laser (TFL) against high-power holmium laser (HPHL) in hands of experienced surgeons for large prostates (≥80ml in volume). Secondary
-
Risks and Side Effects in the Medical Management of Benign Prostatic Hyperplasia Prostate Int. (IF 3.0) Pub Date : 2023-12-02 Abdulghafour Halawani, Ryan Paterson, Tianshuang Zhong, Katie Du, Runhan Ren, Connor M. Forbes
Benign prostatic hyperplasia (BPH) affects up to 80% of men in their lifetime. It causes bladder outflow obstruction, leading to lower urinary tract symptoms, which can have a large impact on quality of life. Lifestyle modifications and pharmacotherapy are often offered as first-line treatment for patients. These include alpha blockers, 5-alpha reductase inhibitors, phosphodiesterase-5 inhibitors,
-
Shifting to transperineal prostate biopsy: A narrative review Prostate Int. (IF 3.0) Pub Date : 2023-11-30 Younsoo Chung, Sung Kyu Hong
Objective To address the limitations and challenges associated with transrectal (TR) biopsy and to present transperineal (TP) biopsy as a viable and potentially safer alternative to TR biopsy. Prostate cancer (PCa) is a significant global health concern. The prevalence of advanced-stage prostate cancer in Asia is higher than that in the United States, emphasizing the need for effective screening and
-
Infectious complications of transrectal prostate biopsy in patients receiving targeted antibiotic prophylaxis after urethral and rectal swab versus standard prophylaxis: A prospective comparative study Prostate Int. (IF 3.0) Pub Date : 2023-11-23 Sotirios Gatsos, Nikolaos Kalogeras, Georgios Dimakopoulos, Michael Samarinas, Anna Papakonstantinou, Efi Petinaki, Vassilios Tzortzis, Stavros Gravas
Background To evaluate the role of targeted antibiotic prophylaxis (TAP) after rectal and urethral swab cultures compared to empiric antibiotic prophylaxis (EAP) for the prevention of infectious complications after transrectal ultrasound-guided prostate biopsy (TRUS-Bx). Methods We conducted a prospective comparative study in 141 patients who underwent TRUS-Bx and were allocated in two groups. The
-
Extracorporeal Shockwave Therapy of the Perineum for male patients with chronic pelvic pain syndrome: A Pilot Study Prostate Int. (IF 3.0) Pub Date : 2023-11-07 K.C.J. Lee, Y.X.T. Law, L. Shen, X.W.G. Pek, Q.Y. Lim, Y.Q. Tan, J.Y. Chia, M.K. Li
Background Chronic Pelvic Pain Syndrome(CPPS) a complex condition that is often difficult to treat and may sometimes require a multidisciplinary team. Among the wide array of treatment options is Extracorporeal Shockwave Therapy(ESWT). However, its role in CPPS remains controversial. The purpose of our study is to assess the efficacy and safety of ESWT of the perineum in male patients with CPPS. Methods
-
Real-World Prostate-Specific Antigen (PSA) reduction and survival outcomes of metastatic hormone-sensitive prostate cancer patients treated with Apalutamide: an observational, retrospective and multicentre study Optimizing Treatment Strategies for Metastatic Hormone-Sensitive Prostate Cancer Patients: Insights from a Real-world Study Prostate Int. (IF 3.0) Pub Date : 2023-11-02 Alicia López-Abad, Miguel Ramírez Backhaus, Gerardo Server Gómez, Enrique Cao Avellaneda, Cristóbal Moreno Alarcón, Pedro López Cubillana, Pablo Yago Giménez, Pedro de Pablos Rodríguez, María José Juan Fita, Miguel Ángel Climent Durán, Iris Guardiola Ruiz, Natalia Vidal Crespo, Miriam Artés Artés, Raúl Montoya Chinchilla, Juan Moreno Avilés, Pablo Luis Guzmán Martínez-Valls, Pedro Ángel López González
Background MHSPC treatment has changed drastically during the last years with the emergence of Androgen Receptor Targeted Agents (ARTA).ARTA combined with ADT has demonstrated better oncological and survival outcomes in these patients. However, the optimal choice among different ARTAs remains uncertain due to their analogous efficacy. Objectives To describe PSA response and oncological outcomes of
-
Prostate-specific antigen doubling time predicts the efficacy of site-directed therapy for oligoprogressive castration-resistant prostate cancer Prostate Int. (IF 3.0) Pub Date : 2023-10-21 Taketo Kawai, Satoru Taguchi, Keina Nozaki, Naoki Kimura, Takahiro Oshina, Takuya Iwaki, Hotaka Matsui, Aya Niimi, Jun Kamei, Yoshiyuki Akiyama, Yuta Yamada, Yusuke Sato, Daisuke Yamada, Tomoyuki Kaneko, Subaru Sawayanagi, Hidetsugu Nakayama, Ryogo Minamimoto, Hideomi Yamashita, Hideyo Miyazaki, Tetsuya Fujimura, Haruki Kume
Background In recent years, site-directed therapies (SDTs) targeting progressive lesions in patients with oligometastatic prostate cancer have attracted attention. However, whether they effectively treat oligoprogressive castration-resistant prostate cancer (CRPC) remains unclear. Here, we investigated the efficacy of SDT in patients with oligoprogressive CRPC and identified prognostic factors. Methods
-
The feasibility of distance to the tumor of biopsy cores to estimate the extracapsular extension Prostate Int. (IF 3.0) Pub Date : 2023-10-14 Chang Lim Hyun, Kyung Kgi Park
Background To investigate the predictive capability of a new parameter, the distance between the fibromuscular capsule and the tumor as measured using a prostate biopsy core (referred to as “distance to the tumor” [DTT]), for the presence of extracapsular extension (ECE). Materials and methods We analyzed specimens obtained from 246 patients diagnosed with prostate cancer. All patients underwent prebiopsy
-
Prognosis after radical prostatectomy in men over 75 years old: long-term results from a single tertiary center Prostate Int. (IF 3.0) Pub Date : 2023-09-28 Jaewon Lee, Jungkeun Song, Gyoohwan Jung, Sang Hun Song, Sung Kyu Hong
Background Despite longer lifespans, guidelines for prostate cancer treatment recommend surgery for those with over 10 years of life expectancy, potentially leaving older patients undertreated. This study examines outcomes of radical prostatectomy in a large cohort of men over 75. Materials and Methods We retrospectively analyzed 636 patients from a pool of 4,500 RP cases at a single tertiary institution
-
Safety and efficacy of tamsulosin 0.4 mg as an initial dose in 1,219 Korean patients with moderate to severe lower urinary tract symptoms: data from a phase IV study Prostate Int. (IF 3.0) Pub Date : 2023-09-21 Jun Ho Lee, Yeon Won Park, Moon-hwa Park, Tag Keun Yoo
Background An initial dose of tamsulosin 0.2 mg is frequently prescribed for Asian men. We investigated the safety and efficacy of tamsulosin 0.4 mg as the initial dose in Korean men with moderate to severe lower urinary tract symptoms (LUTSs) in everyday clinical practice. Materials and methods A phase IV study was conducted in South Korea. Eligible patients were prescribed tamsulosin 0.4 mg for 6 months
-
Cervi Parvum Cornu complex for men with lower urinary tract symptoms: a multicenter, randomized, double-blind, placebo-controlled trial Prostate Int. (IF 3.0) Pub Date : 2023-09-09 Dongho Shin, Byung Il Yoon, Soomin Kim, JunJie Piao, Kyung-Hwa Jeon, Youngjoo Kwon, Sang-Hyuck Park, Young Tae Koo, Jin-Soo Kim, Dong Sup Lee, U-Syn Ha, Sae Woong Kim, Hoon Jang, Woong Jin Bae
Background To evaluate the efficacy and safety of Cervi Parvum Cornu, Angelicae Gigantis Radix and Glycyrrhizae Radix complex (CAG) in men with moderate lower urinary tract symptoms (LUTS). Materials and methods From November 2020 to January 2022, participants with International Prostate Symptom Score (IPSS) of 12–19 in two centers were recruited and randomize into three groups: a CAG 500 mg/day group
-
Artificial intelligence in urologic oncology: the actual clinical practice results of IBM Watson for Oncology in South Korea Prostate Int. (IF 3.0) Pub Date : 2023-09-09 Taeyoung Park, Philip Gu, Chang-Hee Kim, Kwang Taek Kim, Kyung Jin Chung, Tea Beom Kim, Han Jung, Sang Jin Yoon, Jin Kyu Oh
Background Artificial intelligence (AI) is changing our life, including the medical field. Repeated machine learning using big data made various fields more predictable and accurate. In medicine, IBM Watson for Oncology (WFO), trained by Memorial Slone Kettering Cancer Center (MSKCC), was first introduced and applied in 14 countries worldwide. Our study was designed to assess the feasibility of WFO
-
Detection of anterior prostate cancer using a magnetic resonance imaging-transrectal ultrasound fusion biopsy in cases with initial biopsy and history of systematic biopsies Prostate Int. (IF 3.0) Pub Date : 2023-08-31 Masakazu Abe, Ryo Takata, Daiki Ikarashi, Kie Sekiguchi, Daichi Tamura, Shigekatsu Maekawa, Renpei Kato, Mitsugu Kanehira, Takashi Ujiie, Wataru Obara
Background Prostate cancer in the anterior region may be missed on a transrectal systematic biopsy (SBx). Therefore, this study aimed to evaluate the performance of magnetic resonance imaging-transrectal ultrasound (MRI-TRUS) fusion targeted biopsy (TBx) in detecting anterior region cancer in patients with a history of SBxs. Methods Prostate biopsies were performed in 224 patients after multiparametric
-
Evaluation of the efficiency of transurethral enucleation with bipolar energy according to prostate volume for patients with benign prostate hyperplasia Prostate Int. (IF 3.0) Pub Date : 2023-08-22 Byeongdo Song, Sang Hun Song, Seong Jin Jeong
Background This study evaluated the efficiency and safety of transurethral enucleation with bipolar energy (TUEB) using a spatula loop according to prostate volume. Methods We retrospectively evaluated 398 patients who underwent TUEB for benign prostatic hyperplasia at a single tertiary hospital between August 2018 and December 2022. The patients were divided into three groups according to estimated
-
Prostate cancer nomograms and their application in Asian men: a review Prostate Int. (IF 3.0) Pub Date : 2023-08-04 Sridhar Panaiyadiyan, Rajeev Kumar
Nomograms help to predict outcomes in individual patients rather than whole populations and are an important part of evaluation and treatment decision making. Various nomograms have been developed in malignancies to predict and prognosticate clinical outcomes such as severity of disease, overall and recurrence free survival. In prostate cancer, nomograms were developed for determining need for biopsy
-
Prostate-specific antigen kinetics in hypofractionated radiation therapy alone for intermediate- and high-risk localized prostate cancer Prostate Int. (IF 3.0) Pub Date : 2023-07-20 Tae Hoon Lee, Hongryull Pyo, Gyu Sang Yoo, Hyun Moo Lee, Seong Soo Jeon, Seong Il Seo, Byong Chang Jeong, Hwang Gyun Jeon, Hyun Hwan Sung, Minyong Kang, Wan Song, Jae Hoon Chung, Bong Kyung Bae, Won Park
Background This study aimed to evaluate the treatment outcomes and define the prostate-specific antigen (PSA) kinetics as potential prognostic factors in patients with intermediate- or high-risk localized prostate cancer (PCa) who underwent moderately hypofractionated radiation therapy. Methods The study retrospectively reviewed the medical records of 149 patients with intermediate- or high-risk localized
-
Urine spermine and multiparametric magnetic resonance imaging for prediction of prostate cancer in Japanese men Prostate Int. (IF 3.0) Pub Date : 2023-07-20 Shuji Isotani, Peter Ka-Fung Chiu, Takeshi Ashizawa, Yan-Ho Fung, Takeshi Ieda, Toshiyuki China, Haruna Kawano, Fumitaka Shimizu, Masayoshi Nagata, Yuki Nakagawa, Satoru Muto, Ka-Leung Wong, Chi-Fai Ng, Shigeo Horie
Objectives To investigate the role of urine spermine and spermine risk score in predicting prostate cancer (PCa) diagnoses in combination with multiparametric magnetic resonance imaging (mpMRI). Methods Three hundred forty seven consecutive men with elevated prostate-specific antigen (PSA) with mpMRI examination were prospectively enrolled in this study. In 265 patients with PSA levels between 4 and20 ng/ml
-
How to avoid prostate biopsy in men with Prostate Image-Reporting and Data System 3 lesion? Development and external validation of new biopsy indication using prostate health index density Prostate Int. (IF 3.0) Pub Date : 2023-07-11 Jae Yeon Kim, Seong Soo Jeon, Jae Hoon Chung, Seung Soo Lee, Sung-Woo Park
Background To develop a customized prostate biopsy indication using prostate health index density (PHID) combined with multiparametric magnetic resonance imaging (mpMRI) and assess the reliability of the PHID cutoff value in external populations. Methods A total of 521 cognitive MRI/ultrasonography fusion prostate biopsies and biomarker tests for prostate-specific antigen (PSA), free PSA, and PHI were
-
Oral chemotherapeutic agents in metastatic hormone-sensitive prostate cancer: A network meta-analysis of randomized controlled trials Prostate Int. (IF 3.0) Pub Date : 2023-07-04 Yong Seong Lee, Seong Hwan Kim, Jong Hyun Tae, In Ho Chang, Tae-Hyoung Kim, Soon Chul Myung, Myoungsuk Kim, Tuan Thanh Nguyen, Joongwon Choi, Jung Hoon Kim, Jin Wook Kim, Se Young Choi
Background Multiple oral chemotherapeutic agents for metastatic hormone-sensitive prostate cancer (mHSPC) have been developed for conjugated use with conventional androgen deprivation therapy (ADT). Several randomized controlled trials (RCTs) report significant benefits in mHSPC patients. Therefore, we compared overall survival (OS) and progression-free survival (PFS) benefits among considerable mHSPC
-
Screening and validation of novel serum panel of microRNA in stratification of prostate cancer Prostate Int. (IF 3.0) Pub Date : 2023-06-21 Anveshika Manoj, Mohammad K. Ahmad, Gautam Prasad, Durgesh Kumar, Abbas A. Mahdi, Manoj Kumar
Background Owing to the heterogeneous nature of prostate cancer (PCa) and errors in the characterization of the disease, researchers have been trying to unveil molecular biomarkers like microRNA (miRNA) as diagnostic markers. The purpose of our study is to demonstrate the precision of a panel of miRNAs as biomarkers with diagnostic potential for risk stratification. Materials and methods The present
-
Reviving intimacy: Penile rehabilitation strategies for men after prostate cancer treatment Prostate Int. (IF 3.0) Pub Date : 2023-06-08 James Stinson, Nelson Bennett
There have been considerable advances in the field of penile rehabilitation for upwards of 90% of men adversely affected by either short-term or long-term erectile dysfunction after definitive prostate cancer treatment. Despite the evolving landscape of treatment modalities for penile rehabilitation, there is a lack of consensus in the urologic community on the best therapies due to the level of evidence
-
Single-port and multiport robot-assisted radical prostatectomy: A meta-analysis Prostate Int. (IF 3.0) Pub Date : 2023-04-18 Tuan Thanh Nguyen, Ryan W. Dobbs, Huy Gia Vuong, Khoa Quy, Hanh Thi Tuyet Ngo, Anh Tuan Mai, Mai Tran Thi Tuyet, Minh Sam Thai, Ho Yee Tiong, Se Young Choi, Mohammed Shahait, David I. Lee
Objective To compare the perioperative, oncological, and functional outcomes between single-port robot-assisted radical prostatectomy (SP-RARP) and multiport robot-assisted radical prostatectomy (MP-RARP) via a meta-analysis. Methods For relevant articles, three electronic databases, including PubMed, Scopus, and Web of Science, were searched from their inception until January 15, 2022. A meta-analysis
-
Predictive factors for disease progression after salvage radiation therapy in biochemical recurrent patients treated by radical prostatectomy Prostate Int. (IF 3.0) Pub Date : 2023-04-11 Koichi Aikawa, Shoji Kimura, Fumihiko Urabe, Kosuke Iwatani, Kojiro Tashiro, Atsuhiko Ochi, Hirokazu Abe, Manabu Aoki, Takahiro Kimura
Objective Salvage radiation therapy (SRT) is standard treatment for patients after radical prostatectomy (RP). However, the optimal timing of SRT remains to be elucidated. Material and methods We retrospectively reviewed 133 prostate cancer (PCa) patients who underwent SRT for biochemical recurrence after RP. Disease progression was defined as repeated prostate-specific antigen (PSA) level more than
-
Changes of resistance indices after medication in benign prostatic hyperplasia: a prospective study Prostate Int. (IF 3.0) Pub Date : 2023-02-27 Dong Jin Park, Se Yun Kwon, Young Jin Seo, Hye Jin Byun, Kyung Seop Lee
Background This study aimed to determine the relationship between resistive indices (RIs) and changes in prostate size after medical treatment in patients with benign prostatic hyperplasia (BPH). Methods A total of 86 patients with BPH were included in the study, excluding 42 patients with a total prostate volume (TPV) of <30 cc or taking α1-adrenergic blockers and 5α-reductase inhibitors (5ARI) before
-
The oncologic and safety outcomes of low-dose-rate brachytherapy for the treatment of prostate cancer Prostate Int. (IF 3.0) Pub Date : 2023-02-06 Nobumichi Tanaka
Around 40 years have passed since a modern low-dose-rate (LDR) brachytherapy for prostate cancer was introduced. LDR brachytherapy has become one of the definitive treatment options besides radical prostatectomy (RP) and external beam radiation therapy (EBRT). LDR brachytherapy has several advantages over EBRT such as a higher prescribed dose to the prostate gland while avoiding unnecessary irradiation
-
How many cores should be taken from each region of interest when performing a targeted transrectal prostate biopsy? Prostate Int. (IF 3.0) Pub Date : 2023-01-14 Serhat Cetin, Arif Huseyinli, Murat Yavuz Koparal, Ender Cem Bulut, Murat Ucar, Ipek I. Gonul, Sinan Sozen
Background The number of core biopsies required per region of interest (ROI) is controversial, as is the localization of the core to be taken from a lesion. This study aimed to determine the ideal biopsy core number and location in a multiparametric magnetic resonance imaging guided targeted prostate biopsy (TPB), without reducing the clinically significant prostate cancer (csPC) detection rate. Materials
-
Update on the management of benign prostatic hyperplasia and the role of minimally invasive procedures Prostate Int. (IF 3.0) Pub Date : 2023-01-10 Juan V.A. Franco, Pablo Tesolin, Jae Hung Jung
Lower urinary tract symptoms due to benign prostatic hyperplasia constitute a substantial burden, affecting the quality of life of those affected by this condition. While watchful waiting and medical management using a wide array of pharmaceuticals can be effective, surgery has been one of the most definite solutions for those highly affected by this condition. Transurethral resection of the prostate
-
DNA methylation biomarkers distinguishing early-stage prostate cancer from benign prostatic hyperplasia Prostate Int. (IF 3.0) Pub Date : 2023-01-05 Stephanie S. Kim, Seung Cho Lee, Bumjin Lim, Seung-Ho Shin, Mee Young Kim, Sol-Yi Kim, Hyeyeun Lim, Clémentine Charton, Dongho Shin, Hyong Woo Moon, Jinho Kim, Donghyun Park, Woong-Yang Park, Ji Youl Lee
Background DNA methylation markers are considered robust diagnostic features in various cancer types, as epigenetic marks are commonly altered during cancer progression. Differentiation between benign prostatic hyperplasia (BPH) and early-stage prostate cancer (PCa) is clinically difficult, relying on the information of the patient's symptoms or levels of prostate-specific antigen. Methods A total
-
Diagnostic performance of MRI for prediction of recurrent prostate cancer after high-intensity focused ultrasound: a systematic review and meta-analysis Prostate Int. (IF 3.0) Pub Date : 2022-12-24 Hyungwoo Ahn, Sung Il Hwang, Hak Jong Lee, Sang Youn Kim, Jeong Yeon Cho, Hakmin Lee, Sung Kyu Hong, Seok-Soo Byun, Taek Min Kim
Purpose This article aims to evaluate the pooled diagnostic performance control MRI for prediction of recurrent prostate cancer (PCa) after high-intensity focused ultrasound (HIFU). Materials and methods MEDLINE, EMBASE, and Cochrane library databases up to December 31, 2021, were searched. We included studies providing 2×2 contingency table for diagnostic performance of MRI in predicting recurrent
-
Extended versus standard pelvic lymph node dissection yields no difference in 3-year biochemical recurrence rates Prostate Int. (IF 3.0) Pub Date : 2022-12-21 Naoya Nagaya, Kevin J. Chua, Joshua Sterling, Shigeo Horie, Isaac Y. Kim
Background extended pelvic lymph node dissection (ePLND) increases the detection rate of lymph node positive prostate cancer compared to a standard pelvic lymph node dissection (sPLND). However, improvement of patient outcomes remains questionable. Here we report and compare 3-year postoperative PSA recurrence rates between patients that underwent sPLND versus ePLND at the time of prostatectomy. Methods
-
Partial gland ablation using high-intensity focused ultrasound versus robot-assisted radical prostatectomy: a propensity score-matched study Prostate Int. (IF 3.0) Pub Date : 2022-12-17 Gyoohwan Jung, Jung Kwon Kim, Jong Jin Oh, Sangchul Lee, Seok-Soo Byun, Sung Kyu Hong, Hakmin Lee
Background We compared the clinical outcomes of robot-assisted radical prostatectomy (RARP) and partial gland ablation (PGA) using high-intensity focused ultrasound (HIFU) in localized prostate cancer. Methods We analyzed 3,859 patients who had undergone RARP and PGA using HIFU. According to the propensity score for each treatment, 137 patients after PGA were matched to 3,722 patients after RARP at
-
Comparing effects of alpha-blocker management on acute urinary retention secondary to benign prostatic hyperplasia: A systematic review and network meta-analysis Prostate Int. (IF 3.0) Pub Date : 2022-12-15 Yong Nam Gwon, Jae Joon Park, Won Jae Yang, Seung Whan Doo, Jae Heon Kim, Do Kyung Kim
Background To compare the effects of different alpha-blocker regimes on acute urinary retention (AUR) and the success rate of trial without catheter (TWOC) among patients with AUR secondary to benign prostatic hyperplasia (BPH) to determine the most effective regime. Methods A comprehensive literature search was performed using PubMed/Medline, Embase, and Cochrane Library up to June 2021. Studies that
-
Combination of multiparametric magnetic resonance imaging and transperineal template-guided mapping prostate biopsy to determine potential candidates for focal therapy Prostate Int. (IF 3.0) Pub Date : 2022-12-14 Young Hyo Choi, Chung Un Lee, Wan Song, Byong Chang Jeong, Seong Il Seo, Seong Soo Jeon, Hyun Moo Lee, Hwang Gyun Jeon, Seung-Ju Lee
Background We assessed the ability of the combination of multiparametric magnetic resonance imaging (mpMRI) and transperineal template-guided mapping biopsy (TTMB) to determine the eligibility for focal therapy (FT) (hemiablation) in men and compared it with that of histology from radical prostatectomy (RP) specimens. Materials and methods In this study, 120 men who underwent mpMRI, TTMB, and RP in
-
A novel biguanide derivative, IM176, induces prostate cancer cell death by modulating the AMPK-mTOR and androgen receptor signaling pathways Prostate Int. (IF 3.0) Pub Date : 2022-11-18 Yunlim Kim, Sangjun Yoo, Bumjin Lim, Jun Hyuk Hong, Cheol Kwak, Dalsan You, Jung Jin Hwang, Choung-Soo Kim
Background Metformin and phenformin, biguanide derivatives that are widely used to treat type 2 diabetes mellitus, have recently been shown to exert potential anticancer effects in prostate cancer. This study compared the antiprostate cancer effects of the novel biguanide derivative IM176 with those of metformin and phenformin. Methods Prostate cancer cell lines and patient-derived castration-resistant
-
Detection of recurrence sites using 18F-fluorocholine PET/CT in prostate cancer patients with PSA failure Prostate Int. (IF 3.0) Pub Date : 2022-11-12 Dong-Yun Kim, Won Woo Lee, Yoo Sung Song, Sung Kyu Hong, Seok-Soo Byun, Jae-Sung Kim
Background The optimal condition for the clinical application of 18F-fluorocholine positron emission tomography–computed tomography (FCH-PET/CT) to detect recurrence sites in prostate-specific antigen (PSA) failure remains unclear due to the heterogeneity of prostate cancer failure. We aimed to evaluate the detection rate of FCH-PET/CT in prostate cancer patients with PSA failure and to determine the
-
The impact of conventional smoking versus electronic cigarette on the expression of VEGF, PEMPA1, and PTEN in rat prostate Prostate Int. (IF 3.0) Pub Date : 2022-11-11 Alireza Namazi Shabestari, Seyed Saeed Tamehri Zadeh, Parisa Zahmatkesh, Leila Zareian Baghdadabad, Akram Mirzaei, Rahil Mashhadi, Gholamreza Mesbah, Alireza Khajavi, Milad Akbarzadehmoallemkolaei, Mahdi Khoshchehreh, Ramin Rahimnia, Seyed Mohammad Kazem Aghamir
Background The use of electronic cigarettes (e-cigarettes), the alternative to conventional smoking, is increasing considerably worldwide; however, their safety is a matter of debate. Several studies have demonstrated their toxic effects, but no study assessed their effects on the prostate. Objective The current study aimed at evaluating e-cigarettes and conventional smoking prostate toxicity and effects
-
Robotic-assisted radical prostatectomy: learning curves and outcomes from an Australian perspective Prostate Int. (IF 3.0) Pub Date : 2022-10-29 Sachin Perera, Nadil Fernando, Jonathan O'Brien, Declan Murphy, Nathan Lawrentschuk
Background Robot-assisted radical prostatectomy (RARP) has been a treatment for men who suffer from intermediated to high-risk prostate cancer in Australia since 2003. The primary outcomes in relation to learning curves in robotic surgery have been extensively researched in overseas populations, but there is no study from a cohort of Australian surgeons performing RARP. This study aims to highlight
-
Possibilities and limitations of using low biomass samples for urologic disease and microbiome research Prostate Int. (IF 3.0) Pub Date : 2022-10-07 Jung Kwon Kim, Sang Hun Song, Gyoohwan Jung, Byeongdo Song, Sung Kyu Hong
With the dogma of sterile urine no longer held as truth, numerous studies have implicated distinct changes in microbial diversity and composition to diseased subgroups in both benign and malignant urological diseases, ranging from overactive bladder to bladder and prostate cancer. Further facilitated by novel and effective techniques of urine culture and sequencing, analysis of the genitourinary microbiome
-
The effect of systemic hypertension on prostatic artery resistive indices in patients with benign prostate enlargement Prostate Int. (IF 3.0) Pub Date : 2022-09-27 Stephen O. Onigbinde, Christianah M. Asaleye, Abdulkadir A. Salako, Bukunmi M. Idowu, Abimbola O. Onigbinde, Adeyinka Laoye
Background To investigate the effect of systemic hypertension on the prostatic artery resistive indices by a comparative ultrasonographic evaluation of the prostate gland in normotensive and hypertensive patients with benign prostatic enlargement (BPE). Materials and methods The participants had BPE and presented at the outpatient urologic clinic of a tertiary hospital. They were divided into normotensive
-
Irreversible electroporation for prostate cancer using PSMA PET-CT Prostate Int. (IF 3.0) Pub Date : 2022-09-05 Dongho Shin, Chang Eil Yoon, Hyeok Jae Kwon, Hyong Woo Moon, Yong Hyun Park, Hyuk Jin Cho, U-syn Ha, Sung-Hoo Hong, Sonya Youngju Park, Seunggyun Ha, Joo Hyun O, Ie Ryung Yoo, Chansoo Park, Dae Yoon Chi, Ji Youl Lee
Background To demonstrate the clinical usefulness of prostate-specific membrane antigen (PSMA) positron emission tomography (PET) computerized tomography (CT) for irreversible electroporation (IRE) in prostate cancer patients. Methods From January to May 2021, 17 men were diagnosed with localized prostate cancer through preoperative mpMRI and [18F] florastamin PSMA PET-CT imaging, followed by transperineal
-
Current treatment patterns within 1 year after prostate cancer diagnosis in Korean patients over 75 years old: a retrospective multicenter study Prostate Int. (IF 3.0) Pub Date : 2022-08-29 Dong Jin Park, Ho Won Kang, Se Yun Kwon, Young Jin Seo, Kyung Seop Lee, Byung Hoon Kim, Teak Jun Shin, Won Tae Kim, Yong-June Kim, Seok Joong Yun, Sang-Cheol Lee, Jae-Wook Chung, Seock Hwan Choi, Jun Nyung Lee, Hyun Tae Kim, Tae-Hwan Kim, Eun Sang Yoo, Tae Gyun Kwon, Wonho Jung, Yun-Sok Ha
Background We aimed to evaluate the current status of first-line treatment options for prostate cancer in patients aged ≥75 years in Korea. Materials and methods The study included 873 patients diagnosed with biopsy-proven prostate cancer at 5 institutions in Korea from January 2009 to December 2018. Inclusion criteria were aged ≥75 years at diagnosis, prostate biopsy with ≥12 cores, and follow-up
-
Prostate-specific antigen kinetics contributes to decision making for biopsy referral: the predictive implication for PSA retest in patients with elevated PSA levels Prostate Int. (IF 3.0) Pub Date : 2022-08-24 Minoru Kobayashi, Toshiki Kijima, Masahiro Yashi, Takao Kamai
Background It is common to repeat prostate-specific antigen (PSA) measurements for men with PSA elevation before prostate biopsy. In this scenario, they may have considerable psychological distress in fear of the presence of cancer until retests. We assessed possible clinical factors causing transient PSA rise and explored the parameters predictive of subsequent PSA change. Methods As interfering conditions
-
Active surveillance versus nonradical treatment for low-risk men with prostate cancer: a review Prostate Int. (IF 3.0) Pub Date : 2022-08-24 Sachin Perera, Jodie McDonald, Isabella Williams, Jonathan O'Brien, Declan Murphy, Nathan Lawrentschuk
Low-risk prostate cancer has traditionally seen a preference towards avoiding treatment-related harms with active surveillance (AS) and multimodal monitoring protocols utilized to assess for disease progression. Large trials have shown variations in mortality and cancer survival benefit between AS and radical treatment, which has prompted further trials into the management of low-risk disease. Nonradical
-
Retzius-sparing robotic prostatectomy is associated with higher positive surgical margin rate in anterior tumors, but not in posterior tumors, compared to conventional anterior robotic prostatectomy Prostate Int. (IF 3.0) Pub Date : 2022-08-09 Masashi Oshima, Satoshi Washino, Yuhki Nakamura, Tsuzumi Konishi, Kimitoshi Saito, Tomoaki Miyagawa
Objectives The analysis of the oncological outcomes and postoperative continence recovery between conventional robotic-assisted radical prostatectomy (cRARP) and Retzius-sparing RARP (rsRARP), and the effect of the tumor location on them. Materials and methods A total of 317 patients who underwent cRARP (n = 228) or rsRARP (n = 89) from August 2017 to July 2020 were assessed. Patients were categorized
-
Predictors of readmission and impact of same-day discharge in holmium laser enucleation of the prostate Prostate Int. (IF 3.0) Pub Date : 2022-08-05 Carlos Riveros, Elizabeth Di Valerio, Michael Bacchus, Victor Chalfant, Navid Leelani, Devon Thomas, Seyed B. Jazayeri, Joseph Costa
Background Holmium enucleation of the prostate (HoLEP) is becoming the gold standard for the treatment of benign prostatic hyperplasia (BPH). Our objective was to identify predictors of 30-day readmission and the impact of same-day discharge after HoLEP. Methods Using NSQIP data from 2011 to 2019, we identified men who underwent HoLEP for the treatment of BPH. We compared patients based on time of
-
Comparison of intrarectal heated lidocaine gel and periprostatic nerve block for pain control in transrectal ultrasound-guided prostate biopsy: A randomized controlled non-inferiority trial Prostate Int. (IF 3.0) Pub Date : 2022-08-05 Hoon Jang, Hee Nam Moon, Jung Im Kim, Sang Rak Bae, Chang Hee Han, Bong Hee Park
Background To investigate whether intrarectal local anesthesia with heated lidocaine gel (IRLAH) is non-inferior to periprostatic nerve block (PNB) for reducing pain in patients undergoing transrectal ultrasound (TRUS)-guided prostate biopsy. Methods We performed a randomized controlled non-inferiority trial with 100 participants who underwent systematic TRUS-guided, 12-core prostate biopsy from August
-
Challenges in next generation sequencing of homology recombination repair genomic variants in prostate cancer: A nationwide survey and calibration project in China Prostate Int. (IF 3.0) Pub Date : 2022-07-22 Huanwen Wu, Liqun Zhou, Xiaoyan Zhou, Qiang Wei, Nengtai Ouyang, Jianyong Shao, Jian Huang, Zhiyong Liang
Background Homologous Recombination Repair (HRR) is the most reliable and important signaling pathway for repairing DNA damage. We initiated a calibration project to better understand the NGS landscape for HRR gene testing in China, provide indications for testing standardization, and guide clinical practice. Methods A questionnaire was used to collect laboratory information, panel design for HRR gene
-
Temporal changes of PIRADS scoring by radiologists and correlation to radical prostatectomy pathological outcomes Prostate Int. (IF 3.0) Pub Date : 2022-07-19 Sung Kyu Hong, Sang Hun Song, Hak Ju Kim, Hae Sung Lee, Jun Hyun Nam, Seung Bae Lee
Purpose To assess temporal improvement of prostate image reporting and data system (PIRADS) 3-5 lesion correlation to histopathologic findings from radical prostatectomy (RP) in prostate cancer (PCa). Materials and methods A total of 1481 patients who underwent RP for biopsy-proven PCa between 2015 and 2019 were divided into 14 groups of 100 sequential readings for the evaluation of histopathological
-
Molecular genetic testing does not improve the detection of fluoroquinolone resistance before transrectal prostate biopsy Prostate Int. (IF 3.0) Pub Date : 2022-07-06 Michael A. Liss, Harshit Garg, Evgeni V. Sokurenko, Jan E. Patterson, Brian L. Wickes
Background Fluoroquinolone-resistant (FQR) Escherichia coli (E. coli) causes transrectal prostate biopsy infections. We seek to further identify fluoroquinolones resistance by the incorporation of genetic profiling to influence antibiotic selection for transrectal prostate biopsy and whether the addition of this genetic testing could improve the prediction of FQR detection at the time of biopsy. Materials
-
Chronological changes of lower urinary tract symptoms after low-dose-rate brachytherapy for prostate cancer using SpaceOAR® system Prostate Int. (IF 3.0) Pub Date : 2022-06-29 Tomoki Taniguchi, Koji Iinuma, Masahiro Nakano, Makoto Kawase, Shinichi Takeuchi, Daiki Kato, Manabu Takai, Keita Nakane, Takuma Ishihara, Masaya Ito, Tomoyasu Kumano, Masayuki Matsuo, Takuya Koie
Background The aim of this study is to investigate chronological changes of lower urinary tract symptoms (LUTS) in patients with prostate cancer who underwent low-dose-rate brachytherapy (LDR-BT) followed by the insertion of SpaceOAR® system (SpaceOAR). Methods In this retrospective study, 483 patients with localized prostate cancer underwent LDR-BT at the Gifu University Hospital between August 2004
-
Lifestyle habits to prevent the development of benign prostatic hyperplasia: Analysis of Japanese nationwide datasets Prostate Int. (IF 3.0) Pub Date : 2022-06-28 Yukinori Nagakura, Maya Hayashi, Shunichi Kajioka
Objectives Benign prostatic hyperplasia (BPH) refers to nonmalignant hyperplasia of prostate tissue, which causes lower urinary tract symptoms and has become a global public health concern in the aging population. The purpose of this study is to identify modifiable factors, which would prevent or delay BPH development. Methods The association between BPH marker drugs and climate-, socioeconomic-, health
-
Short course of dutasteride in treatment of a refractory category IIIB chronic prostatitis (A placebo-controlled study) Prostate Int. (IF 3.0) Pub Date : 2022-06-20 Ahmed Higazy, A.A. Shorbagy, Mohamed Shabayek, Ahmed Radwan, George N. Halim, Dana Osman, Tarek Osman
Objective To evaluate the short-term efficacy of Dutasteride in the management of chronic prostatitis (CP)/chronic pelvic pain syndrome. Materials and methods A randomized placebo-controlled double-blind study was conducted that including 50 patients diagnosed with CP based on the presence of pelvic pain for ≥3 months of the preceding 6 months. Patients were randomized into 2 equal groups to evaluate
-
Comparison of three questionnaire forms used in the diagnosis of lower urinary tract symptoms: A prospective study Prostate Int. (IF 3.0) Pub Date : 2022-06-09 Muhammet Guzelsoy, Anil Erkan, Murat Ozturk, Salim Zengin, Soner Coban, Ali R. Turkoglu, Akif Koc
Purpose Questionnaire forms (QFs) are used in the evaluation of all patients presenting with lower urinary tract symptoms (LUTSs). Our study aims to investigate the compatibility of the three QFs with each other and to investigate the relationship between education level and complete completion of these forms. Materials and methods A total of 224 patients between February 2018 and February 2019 were